The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes

Clinical Therapeutics

Volumn 37, Issue 6, 2015, Pages 1150-1166

  Whalen, Karen ^a   Miller, Shannon ^a   Onge, Erin St ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

dapagliflozin; empagliflozin; Key words canagliflozin; sodium glucose co transporter 2 inhibitor

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; BALANITIS; BALANOPOSTHITIS; BLADDER TUMOR; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HEMATURIA; HUMAN; HYPOGLYCEMIA; MICTURITION DISORDER; MONOTHERAPY; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; METABOLISM;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84931007816     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.03.004     Document Type: Review

References (69)

1. Diabetes fact sheet. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed November 26, 2014.
2. Statistics about diabetes. American Diabetes Association website. http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav. Accessed November 26, 2014.
3. Heart disease. American Diabetes Association website. http://www.diabetes.org/living-with-diabetes/complications/heart-disease/. Accessed November 26, 2014.
4. The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 329 1993 977 986
5. R.P. Holman, S.K. Paul, and M.A. Bethel 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
6. American Diabetes Association Approaches to glycemic treatment Diabetes Care 38 Suppl 1 2015 S41 S48
7. S. Stark Casagrande, J.E. Fradkin, and S.H. Saydah The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010 Diabetes Care 36 2013 2271 2279
8. Invokana [package insert]. Janssen Pharmaceuticals, Inc. http://www.invokanahcp.com/prescribing-information.pdf. Accessed November 19, 2014.
9. Farxiga [package insert]. Bristol-Myers Squibb Company. http://www.azpicentral.com/farxiga/pi-farxiga.pdf#page=1. Accessed November 19, 2014.
10. Jardiance [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf. Accessed November 19, 2014.
11. J.E. Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 27 2010 136 142
12. J.J. Neumiller, J.R. White, and R.K. Campbell Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus Drugs 70 2010 377 385
13. R. Grempler, L. Thomas, and M. Eckhardt Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 2012 83 90
14. D. Polidori, S. Sha, and S. Mudaliar Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study Diabetes Care 36 2013 2154 2161
15. F.M. Hasan, M. Alsahi, and J.E. Gerich SGLT2 inhibitors in the treatment of type 2 diabetes Diabetes Res Clin Pract 104 2014 297 322
16. S. Kasichayanula, X. Liu, and W.C. Shyu Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects Diabetes Obes Metab 13 2011 47 54
17. K. Strojek, K.H. Yoon, and V. Hruba Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 13 2011 928 938
18. S. Macha, S. Dieterich, and M. Mattheus Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers Int J Clin Pharmacol Ther 51 2013 132 140
19. S. Macha, M. Mattheus, and S. Pinnetti Pharmacokinetics of empagliflozin, a sodium glucose 2 cotransporter-2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomized, open-label, crossover study Diab Res Clin Metab 1 2012 1 7
20. T. Brand, S. Macha, and M. Mattheus Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, coadministered with sitagliptin in healthy volunteers Adv Ther 29 2012 889 899
21. C. Friedrich, K. Metzmann, and P. Rose A randomized, open-label crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers Clin Ther 35 2013 A33 A42
22. S. Kasichayanula, M. Chang, and X. Liu Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin Adv Ther 29 2012 163 177
23. S. Macha, P. Rose, and M. Mattheus Lack of drug-drug interactions between empagliflozin, a sodium glucose cotransporter-2 inhibitor, and warfarin in healthy volunteers Diabetes Obes Metab 15 2013 316 323
24. S. Macha, B. Lang, S. Pinnetti, and U.C. Broedl Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers Int J Clin Pharmacol Ther 52 2014 973 980
25. S. Macha, R. Sennewald, and P. Rose Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers Clin Ther 35 2013 226 235
26. D. Devineni, N. Vaccaro, and D. Polidori Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants Clin Ther 36 2014 698 710
27. T. Heise, M. Mattheus, and H.J. Woerle Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study Clin Ther 2015 [Epub ahead of print]
28. S. Kasichayanula, X. Liu, and S.C. Griffen Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin Diabetes Obes Metab 15 2013 280 283
29. A. Scheen Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus Clin Pharmacokinet 53 2014 295 304
30. D. Devineni, C.R. Curtin, and D. Polidori Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus J Clin Pharmacol 53 2013 601 610
31. S. Macha, S. Mattheus, and S. Pinnetti Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers Clin Drug Investig 20 2013 351 357
32. M. Weir, I. Kline, and J. Xie Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR) Curr Med Res Opin 30 2014 1759 1768
33. K. Stenlöf, W.T. Cefalu, and K.A. Kim Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 2013 372 382
34. K. Stenlöf, W.T. Cefalu, and K.A. Kim Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin 30 2014 163 175
35. F.J. Lavalle-Gonzalez, A. Januszewicz, and J. Davidson Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial Diabetologia 56 2013 2582 2592
36. W.T. Cefalu, L.A. Leiter, and K.H. Yoon Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 2013 941 950
37. J.P. Wilding, G. Charpentier, and P. Hollander Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 67 2013 1267 1282
38. G. Schernthaner, J.L. Gross, and J. Rosenstock Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 36 2013 2508 2515
39. T. Forst, R. Guthrie, and R. Goldenberg Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Diabetes Obes Metab 16 2014 467 477
40. E. Ferrannini, S.J. Ramos, and A. Salsali Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2214 2224
41. K. Kaku, A. Kiyosue, and S. Inoue Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise Diabetes Obes Metab 16 2014 1102 1110
42. C.J. Bailey, N. Iqbal, and C. T'joen Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 14 2012 951 959
43. Del Prato S Nauck Ma, and J.J. Meier Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 2011 2015 2022
44. C.J. Bailey, J.L. Gross, and A. Pieters Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo controlled trial Lancet 375 2010 2223 2233
45. J. Rosenstock, M. Vico, and L. Wei Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 35 2012 1473 1478
46. S.A. Jabbour, E. Hardy, J. Sugg Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 37 2014 740 750
47. J.P. Wilding, V. Woo, and N.G. Soler Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 156 2012 405 415
48. S. Kanada, K. Koiwai, and A. Taniguchi Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus J Diabetes Investig 4 2013 613 617
49. E. Ferrannini, L. Seman, and E. Seewaldt-Becker A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes Metab 15 2013 721 728
50. T. Kadowaki, M. Haneda, and N. Inagaki Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial Adv Ther 31 2014 621 638
51. J. Rosenstock, L.J. Seman, and A. Jelaska Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycemia Diabetes Obes Metab 15 2013 1154 1160
52. H.U. Häring, L. Merker, and E. Seewaldt-Becker Empagliflozin as add-on to metformin plus sulfonyl - urea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 36 2013 3396 3404
53. C.S. Kovacs, V. Seshiah, and R. Swallow Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 16 2014 147 158
54. J. Rosenstock, A. Jelaska, and G. Frappin Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes Care 37 2014 1815 1823
55. E. Ferrannini, A. Berk, and S. Hantel Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes Diabetes Care 36 2013 4015 4021
56. Fulcher G, Matthews DR, Perkovic V, et al. Canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled on sulfonylurea (SU) monotherapy: a CANVAS study. Abstract presented at 73rd Annual American Diabetes Association Scientific Sessions; June 21-25, 2013; Chicago, Ill. Abstract No. 1124-P.
57. D.R. Matthews, G. Fulcher, and V. Perkovic Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes [abstract 764] Diabetologia 55 2012 S314
58. A. Tahrani, A. Barnett, and C. Bailey SGLT inhibitors in management of diabetes Lancet Diabetes Endocrinol 1 2013 140 151
59. D. Vasilakou, T. Karagiannis, and E. Athanasiadou Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Int Med 59 2013 262 274
60. R.V. Oliva, and G.L. Bakris Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors J Am Soc Hypertens 8 2014 330 339
61. R.F. Rosenwasser, S. Sultan, and D. Sutton SGLT-2 inhibitors and their potential in the treatment of diabetes Diabetes Metab Syndr Obes 6 2013 453 467
62. B. Neal, V. Perkovic, and D. de Zeeuw Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - a randomized placebo-controlled trial Am Heart J 166 2013 217 223
63. F.D.A. Briefing Document (NDA 204042) Invokana (canagliflozin) tablets. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Accessed December 5, 2014.
64. M. Zhang, L. Zhang, and B. Wu Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials Diabetes Metab Res Rev 30 2014 204 221
65. F.D.A. Briefing Document (NDA 202293) Dapagliflozin oral tablets, 5 and 10 mg. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378076.pdf. Accessed December 4, 2014.
66. B. Zinman, S. Inzucchi, and J. Lachin Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMETM) Cardiovasc Diabetol 13 2014 102
67. S.A. Nisly, D. Kolanczyk, and A. Walton Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes Am J Health Syst Pharm 70 2013 311 319
68. Meta-analysis in post-marketing surveillances for SGLT2 inhibitors in patients with type 2 diabetes mellitus. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02284269?term=empagliflozin+and+cancer&rank=1. Accessed January 27, 2015.
69. A.J. Garber, M.J. Abrahamson, and J.I. Barzilay AACE comprehensive diabetes management algorithm 2013 Endocr Pract 19 2013 327 336